The musculoskeletal pain market is entering a phase of significant transformation as pharmaceutical companies pivot toward non-opioid, targeted treatments. Currently, the landscape relies heavily on NSAIDs, corticosteroid injections, and viscosupplements—treatments that offer temporary relief but fail to alter disease progression. Market analysts project that the rise of regenerative medicine and disease-modifying osteoarthritis drugs (DMOADs) will redefine the standard of care by 2036.

Key players such as Mesoblast, Taiwan Liposome Company, and Biosplice are leading this shift with candidates currently in late-stage clinical trials. Mesoblast’s Rexlemestrocel-L, for instance, is being evaluated for its potential to address chronic low back pain through a regenerative mechanism, while Taiwan Liposome’s TLC599 aims to provide sustained relief for knee osteoarthritis for up to six months. These innovations arrive as clinicians and patients increasingly seek alternatives to opioids and invasive surgeries, driven by the growing burden of age-related degenerative conditions. The United States remains the largest market for these interventions, though growth is expected across the EU4, the United Kingdom, and Japan as new regulatory approvals follow recent clinical milestones.